Active Biotech AB Year-end Report, January - December 2009

(Thomson Reuters ONE) - ·           Laquinimod ? Phase III program proceeding according to plan·           57-57 ? exploratory clinical trial in progress·           RhuDex((TM) )? additional preclinical studies to be conducted in2010·           ANYARA ? Phase III trials proceeding according to plan·           TASQ ? primary endpoint met in clinical Phase II·           ISI ? project proceeding according to plan·           Net sales of SEK 10.8 M (53.5)·           Operating loss of SEK 219.6 M (loss: 184.6)·           Loss after tax of SEK 224.0 M (loss: 181.6)·           Loss per share for the period amounted to SEK 3.81 (loss: 3.66)For further information, please contact:Tomas LeandersonPresident and CEOTel: +46 (0)46-19 20 95G? ForsbergVP Investor Relations & Business DevelopmentTel: +46 (0)46-19 11 54HansKolamCFOTel: +46 (0)46-19 20 44Active Biotech AB(Corp. Reg. No. 556223-9227)Box 724, 220 07 LundTel: +46 (0)46-19 20 00Fax +46 (0)46-19 11 00This report is also available at www.activebiotech.com[HUG#1383189] Active Biotech AB Year-end Report, January ? December 2009: http://hugin.info/1002/R/1383189/341980.pdf

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 11.02.2010 - 08:32 Uhr
Sprache: Deutsch
News-ID 12346
Anzahl Zeichen: 0

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 170 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech AB Year-end Report, January - December 2009"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech